Disease modeling using induced pluripotent stem cells (iPSC) from patients and their CRISPR-Cas9 gene edited iPSC. The current focus is on Alzheimer’s disease (AD) Frontotemporal dementia (FTD), Glaucoma, Epilepsy and Schizophrenia.
| Website | https://ivh.ku.dk/english/research/pathobiological-sciences/freude-group/ |
| Revenue | $422.8 million |
| Employees | 6 (0 on RocketReach) |
| Founded | 2015 |
| Technologies |
JavaScript
,
HTML
,
PHP
+8 more
(view full list)
|
| Industry | Biotechnology |
| Keywords | Stem Cell Research, Crispr Gene Editing, Neurological Disorders, Regenerative Medicine, Drug Discovery Platform, Therapeutic Target Identification, Glaucoma Research, Epilepsy Research, Schizophrenia Research, Precision Medicine, Translational Research, Stem Cell Therapy |
| Competitors | Medtronic, Boston Scientific, Elekta, Neurocrine Biosciences, NeuroPace, CureMetrix, Axovant Sciences Ltd, NeuroSigma, Blackfynn, Neurotech.com +42 more (view full list) |
Looking for a particular BrainStem employee's phone or email?
BrainStem Questions
The BrainStem annual revenue was $422.8 million in 2026.
Related Companies
G2Crowd Trusted
300K+
Plugin Users
